Ionis' Dawnzera reduces HAE attack rates 95% over two years in extension study

By Public Technologies15:01 (UTC), 12 November 2026 Updated

Ionis Pharmaceuticals will present two-year DAWNZERA (donidalorsen) results at the 2026 American College of Allergy, Asthma & Immunology meeting.
OASISplus extension results showed sustained reductions in hereditary angioedema attacks with dosing every four or eight weeks.
Patients switching from other long-term preventive therapies maintained lower attack rates than on their prior treatments over two years.
No new safety signals emerged; most adverse events were mild or moderate, with no serious treatment-related events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611121000BIZWIRE_USPR_____20261111_BW437603) on November 12, 2026, and is solely responsible for the information contained therein.